Your browser doesn't support javascript.
loading
How do patient reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients.
Coyle, Conor; Watson, Lily; Whately-Smith, Caroline; Brooke, Mel; Kiltz, Uta; Lubrano, Ennio; Queiro, Ruben; Trigos, David; Brandt-Juergens, Jan; Choy, Ernest; D'Angelo, Salvatore; Delle Sedie, Andrea; Dernis, Emmanuelle; Wirth, Théo; Guis, Sandrine; Helliwell, Philip; Ho, Pauline; Hueber, Axel; Joven, Beatriz; Koehm, Michaela; Morales, Carlos Montilla; Packham, Jon; Pinto Tasende, Jose Antonio; Garcia, Felipe Julio Ramirez; Ruyssen-Witrand, Adeline; Scrivo, Rossana; Twigg, Sarah; Welcker, Martin; Soubrier, Martin; Gossec, Laure; Coates, Laura C.
Afiliação
  • Coyle C; Oxford University, John Radcliffe Hospital, Oxford University Hospitals, Oxford, UK.
  • Watson L; University of Bristol, Department of Cellular and Molecular Medicine, Bristol, UK.
  • Whately-Smith C; Consultant Biostatistician, Whately-Smith Ltd Herts, UK.
  • Brooke M; Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Bath, UK.
  • Kiltz U; Ruhr-Universität Bochum, and Rheumazentrum Ruhrgebiet, Bochum, Germany.
  • Lubrano E; Academic Rheumatology Unit, Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy.
  • Queiro R; Rheumatology & ISPA Translational Immunology Division, Faculty of Medicine, Rheumatology Service & the Principality of Asturias Institute for Health Research (ISPA), Universidad de Oviedo, Oviedo, Spain.
  • Trigos D; Acción Psoriasis, Barcelona, Spain, Spain.
  • Brandt-Juergens J; Rheumatologische Schwerpunktpraxis, Bundesallee 104/105, Berlin, 12161, Germany.
  • Choy E; CREATE Centre, Division of Infection and Immunity, Cardiff University, Cardiff, UK.
  • D'Angelo S; Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy.
  • Delle Sedie A; Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
  • Dernis E; Rheumatology Department, Centre Hospitalier du Mans, Le Mans, France.
  • Wirth T; Rheumatology Department, INSERM UMRs1097 Autoimmune Arthritis, Aix Marseille University, Marseille, France.
  • Guis S; Rheumatology department, Aix Marseille University, Arthrites Autoimmunes, Marseille, France.
  • Helliwell P; University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK.
  • Ho P; The Kellgren Centre for Rheumatology, Manchester University NHS Foundation Trust, Manchester, UK.
  • Hueber A; Division of Rheumatology, Klinikum Nürnberg, Paracelsus Medical University, Nürnberg, Germany.
  • Joven B; Rheumatology Department, Hospital Universitario 12 Octubre, Madrid, ES. & Universidad Complutense de Madrid, Avda de Córdoba sin, Madrid, 28041, Spain.
  • Koehm M; Rheumatology, Universitiy Hospital Frankfurt, Fraunhofer-Institute for Translational Medicine and Cluster of Excellence Immune-Mediated Diseases CIMD, Frankfurt am Main, Germany.
  • Morales CM; Rheumatology Department, Hospital Universitario Salamanca, Salamanca, Spain.
  • Packham J; Academic Unit of Population and Lifespan Sciences, University of Nottingham, UK.
  • Pinto Tasende JA; Rheumatology Department, INIBIC. CHU A Coruña, Spain.
  • Garcia FJR; Arthritis Unit, Rheumatology Department, Hospital Clinic, Barcelona, Spain.
  • Ruyssen-Witrand A; Rheumatology Center, Toulouse University Hospital, CIC 1436 Inserm, Rheumatology, Tolouse, France & Paul Sabatier University, Toulouse III Toulouse, France.
  • Scrivo R; Rheumatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
  • Twigg S; Rheumatology, Bradford Teaching Hospitals NHS foundation trust, Bradford, UK.
  • Welcker M; MVZ für Rheumat ologie Dr M. Welcker GmbH, Bahnhofstr. 32, Planegg, 82152, Germany.
  • Soubrier M; Rheumatology Departement, Gabriel-Montpied Teaching Hospital of Clermont-Ferrand, France.
  • Gossec L; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, FR. & AP-HP, Pitié-Salpêtrière hospital, Rheumatology department, Paris, France.
  • Coates LC; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Article em En | MEDLINE | ID: mdl-38191998
ABSTRACT

OBJECTIVES:

The ASSIST study investigated prescribing in routine psoriatic arthritis (PsA) care and whether the patient reported

outcome:

PsA Impact of Disease questionnaire (PsAID-12), impacted treatment. This study also assessed a range of patient and clinician factors and their relationship to PsAID-12 scoring and treatment modification.

METHODS:

Patients with PsA were selected across the UK and Europe between July 2021-March 2022. Patients completed the PsAID questionnaire, with the results shared with their physician. Patient characteristics, disease activity, current treatment methods, treatment strategies, medication changes and patient satisfaction scores were recorded.

RESULTS:

503 patients recruited. 36.2% had changes made to treatment, 88.8% of this had treatment escalation. Overall, the mean PsAID-12 score was higher for patients with treatment escalation; the PsAID-12 score was associated with odds of treatment escalation (OR 1.58; p< 0.0001). However, most clinicians reported PsAID-12 did not impact their decision to escalate treatment, instead supporting treatment reduction decisions. Physician's assessment of disease activity had the most statistically significant effect on likelihood of treatment escalation, (OR = 2.68, per 1-point score increase). Escalation was more likely in patients not treated with biologic therapies. Additional factors associated with treatment escalation included patient characteristics, physician characteristics, disease activity and disease impact.

CONCLUSION:

This study highlights multiple factors impacting treatment decision making for individuals with PsA. PsAID-12 scoring correlates with multiple measures of disease severity and odds of treatment escalation. However, most clinicians reported the PsAID-12 did not influence treatment escalation decisions. PsAID scoring could be used to increase confidence in treatment de-escalation.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido